Mesothelioma Prognosis

Mesothelioma is an aggressive cancer with a long latency period and usually goes undiagnosed until it’s in advanced stages, making it more difficult to treat. Because of this, prognosis is often poor, with most mesothelioma patients living an average of 1 to 2 years after diagnosis.

Key Points about Mesothelioma Prognosis

  • The prognosis of a mesothelioma patient depends on the stage of the cancer, the specific cell type, and the patient’s age and overall health.
  • Mesothelioma patients generally live 1 to 2 years after diagnosis.
  • Recent advancements in detection techniques and treatment options are helping to improve prognosis for many mesothelioma patients.

A mesothelioma patient’s prognosis details how the cancer will progress following diagnosis and often includes an estimate for how long the patient can expect to live, or the life expectancy. Recent research and clinical trials have led to steady progress in crucial areas like detection, diagnosis, and treatment, improving prognosis and providing hope for many mesothelioma patients. While a mesothelioma prognosis is often bleak, there is hope, and there are patients who survive longer than 10 years.

Understanding Terminology

Prognosis

A projection for how a patient’s disease is expected to progress.

Survival Rate

A percentage that shows how many patients live a given amount of time following diagnosis.

Life Expectancy

The length of time after a diagnosis that a patient is likely to live. This estimate depends on success of treatment and other factors, and is usually included in a prognosis.

Primary Factors that Affect your Prognosis

Three main factors are evaluated by physicians when determining a mesothelioma patient’s prognosis: type of mesothelioma (including cell type), the cancer’s stage, and the patient’s overall health.

Type of Mesothelioma

The type of mesothelioma a patient has is classified by where the cancer is located (the lungs, abdomen, or heart) and by the types of mesothelioma cells that are involved (epithelioid, sarcomatoid, and biphasic). Both the location of mesothelioma and cell type affect a patient’s prognosis.

Location

Peritoneal mesothelioma, which is located in the abdomen, has a more favorable prognosis than both pleural mesothelioma (located in the lungs) and pericardial mesothelioma (located in the heart). Pericardial mesothelioma patients generally have the poorest prognosis.

Cell Type

The types of cells which make up your tumor (histology) impacts your prognosis as well. Patients with epithelial mesothelioma survive longer, on average, than those with sarcomatoid mesothelioma. Survival of patients with biphasic mesothelioma falls between patients with epithelial and sarcomatoid mesothelioma.

Median Survival Times for Patients By Cell Type

Epithelial
19 mo
Biphasic
13 mo
Sarcomatoid
Pleural
8 mo

Stage

The stage of a mesothelioma patient’s cancer is determined primarily by tumor size and how much, if at all, it has grown or spread (metastasized) to other parts of the body. The earlier mesothelioma is detected and diagnosed, the better the prognosis will be. Late stage mesothelioma (Stage III and IV) is very difficult to treat curatively.

Overall health

Mesothelioma patients who are in poorer health due to age or whose immune systems are weakened for reasons outside the mesothelioma diagnosis are less able to tolerate more aggressive treatments necessary to improve prognosis.

Ways to Improve your Prognosis

Mesothelioma prognosis has benefited in recent years from advancements in diagnostic methods and treatment, often discovered in clinical trials. The best way to improve a mesothelioma patient’s prognosis, however, is to catch the disease as early as possible.

Conventional Treatments

Depending on a patient’s eligibility, opting for conventional mesothelioma treatments including surgery, chemotherapy, and radiation can also improve prognosis. Certain combinations of these treatments have also shown better success rates than others. If you’ve been diagnosed with mesothelioma, be sure to consult with your doctor about all the available treatment options along with how eligible you may be for each.

Early Detection

Early detection allows mesothelioma patients to have more treatment options and improved chances of success. Because of mesothelioma’s long latency period, this has generally been very challenging to do. There have been advancements in early detection, however, including certain blood tests.

If you believe you’ve been exposed to asbestos, the only proven cause of mesothelioma, you should talk to your doctor immediately.

Clinical Trials

If you have been diagnosed with mesothelioma, there are some steps you can take to improve your prognosis and quality of life, including maintaining a healthy overall lifestyle and keeping stress low. For some qualified patients, enrolling in a clinical trial can be another way to improve prognosis.

Considerable resources are being spent to improve mesothelioma treatment, and a large part of these resources is spent on clinical trials. Enrolling in a clinical trial does not mean you have to give up standard treatment. Many patients have benefited from the kinds of experimental treatments researched in these trials, such as gene therapy and immunotherapy.

Send Me a Free Guide Guide Photo

1 Where should we overnight your free guide?

2 Recipient information.

    Sources & About the Writer [+]
    • 1 Rusch VW, Giroux D, Kennedy C, et al. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. Journal of Thoracic Oncology. 2012;7(11):1631-1639. doi:10.1097/JTO.0b013e31826915f1
    • 2 Levy AD, Arnaiz J, Shaw JC, Sobin LH. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics. Mar-Apr 2008;28(2):583-607; quiz 621-582. doi:10.1148/rg.282075175
    • 3 Alexander HR, Burke AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. Journal of Gastrointestinal Oncology. 2016;7(1):79-86. doi:10.3978/j.issn.2078-6891.2015.134
    • 4 Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. Nov 2006;130(11):1654-1661. doi:10.1043/1543-2165(2006)130[1654:psohpi]2.0.co;2
    • 5 Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. Jan 1998;16(1):145-152.
    • 6 Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. Mar 1998;113(3):723-731.
    • 7 Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. Journal of Thoracic Oncology. 2007;2(10):957-965.
    • 8 Frost G, Darnton A, Harding A-H. The Effect of Smoking on the Risk of Lung Cancer Mortality for Asbestos Workers in Great Britain (1971–2005). Annals of Occupational Hygiene. April 1, 2011 2011;55(3):239-247. doi:10.1093/annhyg/meq089
    • About The Writer Photo of Dan Heil Dan Heil

      Dan is a contributing writer for The Mesothelioma + Asbestos Awareness Center. He hopes to help educate on everything related to a mesothelioma diagnosis and answer any questions patients or family members may have.